Arsenic trioxide: an emerging therapy for multiple myeloma.
about
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyThe effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cellsTrials of arsenic trioxide in multiple myeloma.Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines.The sensitivity of digestive tract tumor cells to As2O3 is associated with the inherent cellular level of reactive oxygen species.Treatment of multiple myeloma: an emphasis on new developments.Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells.Common complaints, difficult diagnosis: multiple myeloma.Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.The combination of arsenic and cryptotanshinone induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast cancer cells.Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide.Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide.Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells.
P2860
Q33962155-28A8E5D1-6023-4A46-99A0-15A4BA33DD80Q33965775-23ABED22-8577-488D-A61A-5062B0187848Q35569458-92C635A8-F9D0-4996-8305-6856995EA15FQ36224699-7B96A4C7-0DD8-4840-9E08-1F3F55CD9F0EQ36309105-67B3B24B-917F-4A69-AD1C-4F12659486F9Q36438215-3D797D0C-F2BC-408E-B988-00783670E9C4Q36453943-A207A6A4-17D1-4B4A-80C6-9FE792C202BEQ36471721-917A721F-08DE-44F6-A66B-A018F1E820E6Q38676278-4556B9A8-F173-4EE3-94D7-296C1F62FB98Q38938902-881206E7-50C0-49BD-9792-9CBF9BE2FE5CQ39175673-5E12C88C-BAD2-43FF-A48A-CE6038B2A67DQ44670178-15707B78-233D-43C1-9111-186C05C1F9ADQ45114054-D56AE4EA-FCBD-43BE-A393-B041D91E5A0A
P2860
Arsenic trioxide: an emerging therapy for multiple myeloma.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Arsenic trioxide: an emerging therapy for multiple myeloma.
@ast
Arsenic trioxide: an emerging therapy for multiple myeloma.
@en
Arsenic trioxide: an emerging therapy for multiple myeloma.
@nl
type
label
Arsenic trioxide: an emerging therapy for multiple myeloma.
@ast
Arsenic trioxide: an emerging therapy for multiple myeloma.
@en
Arsenic trioxide: an emerging therapy for multiple myeloma.
@nl
prefLabel
Arsenic trioxide: an emerging therapy for multiple myeloma.
@ast
Arsenic trioxide: an emerging therapy for multiple myeloma.
@en
Arsenic trioxide: an emerging therapy for multiple myeloma.
@nl
P1433
P1476
Arsenic trioxide: an emerging therapy for multiple myeloma.
@en
P2093
P356
10.1634/THEONCOLOGIST.6-SUPPL_2-17
P478
P577
2001-01-01T00:00:00Z